Stan Smith Acquires 15,000 Shares of MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Stan Smith purchased 15,000 shares of the firm’s stock in a transaction dated Tuesday, November 25th. The shares were acquired at an average cost of $0.98 per share, with a total value of $14,700.00. Following the completion of the purchase, the director directly owned 1,349,289 shares in the company, valued at approximately $1,322,303.22. This represents a 1.12% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Stan Smith also recently made the following trade(s):

• On Monday, November 24th, Stan Smith acquired 10,000 shares of MAIA Biotechnology stock. The stock was acquired at an average cost of $0.99 per share, for a total transaction of $9,900.00.
• On Wednesday, October 1st, Stan Smith bought 19,230 shares of MAIA Biotechnology stock. The stock was acquired at an average cost of $1.30 per share, with a total value of $24,999.00.

MAIA Biotechnology Price Performance

MAIA stock traded up $0.09 during midday trading on Wednesday, hitting $1.06. The company’s stock had a trading volume of 382,828 shares, compared to its average volume of 393,561. The company’s fifty day moving average price is $1.36 and its 200 day moving average price is $1.58. MAIA Biotechnology, Inc. has a twelve month low of $0.87 and a twelve month high of $2.74. The stock has a market capitalization of $39.25 million, a P/E ratio of -1.45 and a beta of -0.01.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of MAIA. Geode Capital Management LLC increased its position in shares of MAIA Biotechnology by 3.6% during the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock worth $400,000 after purchasing an additional 7,746 shares during the last quarter. Centerpoint Advisory Group bought a new position in shares of MAIA Biotechnology in the second quarter valued at $28,000. Marshall Wace LLP bought a new position in shares of MAIA Biotechnology in the second quarter valued at $29,000. Jane Street Group LLC acquired a new position in MAIA Biotechnology during the second quarter worth $52,000. Finally, Centric Wealth Management raised its position in MAIA Biotechnology by 740.2% during the second quarter. Centric Wealth Management now owns 573,398 shares of the company’s stock worth $1,032,000 after acquiring an additional 505,150 shares in the last quarter. 5.65% of the stock is owned by institutional investors and hedge funds.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.